[Protocol of combined surgical and polychemico-immunoradiologic therapy of stage T2N2MO lung cancer].
Preliminary data on the use of a combined surgical-polychemical-immunoradiotherapy protocol in the treatment of 13 T2N2M0 lung cancer patients are reported. The results are compared with those obtained in a 13 patient control group, homogenous by histotype, stage and surgical treatment who were given no other therapy. At 24 months the average survival rate in the first group was 61.5% compared to 15.3% in the second. It was significant that survival at 24 months after pneumonectomy rose from 16.6% to 50% and even more significantly survival after lobectomy rose from 14.2% to 71.4%.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D006801:Humans; D007167:Immunotherapy; D008175:Lung Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging; D011013:Pneumonectomy; D011182:Postoperative Care; D011868:Radioisotopes / Q000627:therapeutic use
D011868:Radioisotopes
Protocollo di trattamento combinato, chirurgico e polichemio-immuno-radioterapico del carcinoma polmonare allo stadio T2N2M0.